BTIG has reiterated a Buy rating for AtriCure (ATRC) with a price target of $54. This decision aligns with a positive trend of analyst ratings for ATRC, including recent Buy or Overweight ratings from Needham, JP Morgan, and Canaccord Genuity. Analysts collectively project an average target price of $53.38, implying a 61.89% upside from the current price, further supported by GuruFocus’ estimated GF Value suggesting a 45.34% upside.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
AtriCure (ATRC): BTIG Reiterates Buy Rating and $54 PT | ATRC St
BTIG has reiterated a Buy rating for AtriCure (ATRC) with a price target of $54. This decision aligns with a positive trend of analyst ratings for ATRC, including recent Buy or Overweight ratings from Needham, JP Morgan, and Canaccord Genuity. Analysts collectively project an average target price of $53.38, implying a 61.89% upside from the current price, further supported by GuruFocus’ estimated GF Value suggesting a 45.34% upside.